ClinicalTrials.gg
CompletedNCT04632992MyTACTICUpdated Jan 8, 2025Results posted

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

A Phase 2 interventional study of Entrectinib and Inavolisib in Advanced Unresectable or Metastatic Solid Malignancy, sponsored by Genentech, Inc.. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers.

Patients will be enrolled based on local testing performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory. The multi-arm structure of the MyTACTIC study allows patients with solid tumors to be treated with a drug or drug regimen tailored to their biomarker identified at screening.

02

Conditions studied

  • Advanced Unresectable or Metastatic Solid Malignancy
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of advanced unresectable or solid
  • Positive biomarker results from a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory and availability of a full report of the testing results. This may be from a tissue or blood sample.
  • Evaluable or
  • (ECOG) Performance Status 0-2
  • ≥8 weeks
  • Adequate hematologic and end-organ function, as defined in the protocol, obtained within 14 days prior to initiation of study treatment
  • Agrees to take measures to prevent pregnancy in the patient or partner
  • In addition to the general inclusion criteria above, there are treatment-specific inclusion criteria that apply for each respective treatment arm (as detailed in the protocol)

Exclusion criteria

Exclusion Criteria:

  • Current participation or enrollment in another therapeutic clinical trial
  • Symptomatic or actively progressing (asymptomatic patients with treated or untreated CNS metastases may be eligible, provided all protocol-defined criteria are met)
  • History of , unless noted otherwise for a specific treatment arm of the study
  • Wide field radiotherapy within 14 days prior to start of study treatment
  • Stereotactic radiosurgery within 7 days prior to start of study treatment
  • Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infections, or any active infection that, in the opinion of the investigator, could impact patient safety
  • Receipt of any anticancer drug/biologic or treatment 21 days prior to Cycle 1, Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle 1, Day 1 (androgen blockage may be continued for male patients with prostate cancer)
  • Known (HIV), virus (HCV), or virus (HBV) infection with status outside of study-allowed criteria
  • History of or concurrent serious medical condition or abnormality in clinical laboratory tests that precludes the patient's safe participation in and completion of the study or confounds the ability to interpret data from the study
  • History of other than disease under study within 3 years prior to screening, with the exception of malignancies with a negligible risk of or death
  • Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
  • Major surgical procedure, other than for diagnosis, or significant traumatic injury within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
  • Significant cardiovascular disease, such as cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • In addition to the general exclusion criteria above, there are treatment-specific exclusion criteria that apply for each respective treatment arm (as detailed in the protocol)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Arm A: Entrectinib

    Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.

    Drug: Entrectinib

  • Experimental
    Arm B: Inavolisib

    Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.

    Drug: Inavolisib

  • Experimental
    Arm C: Alectinib

    Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.

    Drug: Alectinib

  • Experimental
    Arm D: Ipatasertib

    Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.

    Drug: Ipatasertib

  • Experimental
    Arm E: Atezolizumab + Investigator's Choice of Chemotherapy

    Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).

    Drug: Atezolizumab · Drug: Investigator's Choice of Chemotherapy

  • Experimental
    Arm F: Trastuzumab Emtansine + Atezolizumab

    Participants in this treatment arm must have a positive tumor biomarker result for human epidermal growth factor receptor 2 (HER2) mutations or amplification without known TMB high or MSI high/dMMR.

    Drug: Atezolizumab · Drug: Trastuzumab Emtansine

  • Experimental
    Arm G: PH FDC SC

    Participants in this treatment arm must have a positive tumor biomarker result for HER2 mutation or amplification without known TMB high or MSI high/dMMR.

    Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf

  • Experimental
    Arm H: PH FDC SC + Investigator's Choice of Chemotherapy

    Participants in this treatment arm must have a positive tumor biomarker result for HER2 mutation or amplification without known TMB high or MSI high/dMMR.

    Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf · Drug: Investigator's Choice of Chemotherapy

  • Experimental
    Arm I: Trastuzumab Emtansine + Tucatinib

    Participants in this treatment arm must have a positive tumor biomarker result for HER2 mutation or amplification without known TMB high or MSI high/dMMR.

    Drug: Trastuzumab Emtansine · Drug: Tucatinib

  • Experimental
    Arm J: Trastuzumab Emtansine + Atezolizumab

    Participants in this treatment arm must have positive tumor biomarker results for HER2 mutation or amplification and TMB high or MSI high/dMMR.

    Drug: Atezolizumab · Drug: Trastuzumab Emtansine

  • Experimental
    Arm K: Ipatasertib + Atezolizumab

    Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.

    Drug: Ipatasertib · Drug: Atezolizumab

  • Experimental
    Arm L: Ipatasertib + Atezolizumab

    Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.

    Drug: Ipatasertib · Drug: Atezolizumab

  • Experimental
    Arm M: Ipatasertib + Paclitaxel

    Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.

    Drug: Ipatasertib · Drug: Paclitaxel

  • Experimental
    Arm N: Atezolizumab + Tiragolumab

    Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.

    Drug: Atezolizumab · Drug: Tiragolumab

  • Experimental
    Arm O: Pralsetinib

    Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.

    Drug: Pralsetinib

Interventions

  • Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.

    Also known as: Rozlytrek™, RG6268, RO7102122

  • Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.

    Also known as: GDC-0077, RG6114, RO7113755

  • Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.

    Also known as: Alecensa®, RG7853, RO5424802

  • Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.

    Also known as: GDC-0068, RG7440, RO5532961

  • Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).

    Also known as: Tecentriq®, RG7446, RO5541267

  • Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.

    Also known as: Kadcyla®, RG3502, RO5304020

  • DrugPertuzumab, Trastuzumab, and Hyaluronidase-zzxf

    Drug page: Pertuzumab/Trastuzumab/Hyaluronidase-zzxf

    PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.

    Also known as: PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574

  • Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.

    Also known as: Tukysa™

  • DrugInvestigator's Choice of Chemotherapy

    Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.

  • The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.

  • Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.

    Also known as: RG6058, RO7092284, MTIG7192A

  • Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.

    Also known as: GAVRETO™, RG6396, RO7499790

This study also gives Trastuzumab, Pertuzumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Primary Central Nervous System (CNS) Tumors

    Confirmed objective response rate (cORR)=percentage of participants with best response as complete response (CR) or partial response (PR) for measurable disease \& CR for non-measurable disease. Confirmation=CR/PR on 2 consecutive visits ≥4 weeks apart for 3-week cycles \& ≥6 weeks apart for 4-week cycles. Per RECIST, CR=disappearance of all target lesions. PR= ≥30% decrease in sum of diameters of target lesions, in absence of CR. Per RANO, CR=complete disappearance of all measurable \& non-measurable disease for ≥4 weeks; no new lesions/abnormality on T2/FLAIR imaging; stable/improved non-enhancing lesions; participants must be off corticosteroids or on physiological doses; clinical status stable/improved. PR= ≥50% decrease in the sum of products of perpendicular diameters of measurable enhancing lesions on T2/FLAIR imaging for ≥4 weeks; no progression of non-measurable T1 disease; stable/improved non-enhancing lesions; corticosteroid dose ≤ baseline; clinical status stable/improved.

    Time frame: Up to 32 months

Secondary outcomes

  1. Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria

    PFS=time from start of treatment to the first occurrence of disease progression (PD) or death from any cause, whichever occurs first, per RECIST v1.1, or RANO. Per RECIST, PD=≥20% increase in sum of diameters of lesions, using the smallest sum during the study as reference, including baseline (BL). Per RANO, PD= ≥25% increase in sum of products of perpendicular diameters of enhancing lesions compared to smallest tumor measurement at BL/best response, on stable/increasing corticosteroids (CS) dose; Significant/ ≥25% increase of T2/FLAIR non-enhancing lesion on stable/increasing CS dose compared to BL/best response after therapy start; Presence of new lesions/increase of enhancement; Clear progression of non-measurable disease; Definite clinical deterioration only due to tumor/decrease in CS dose; Failure to return for evaluation due to death/deterioration. Kaplan-Meier methodology was used to estimate PFS; patients without an event were censored on the last available assessment day.

    Time frame: Time from start of treatment to the first occurrence of disease progression or death from any cause (Up to 32 months)

  2. Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria

    DOR was defined as the time from the date of the first confirmed complete response (CR) or partial response (PR) to disease progression (PD) or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. CR \& PR were defined per RECIST or RANO as outlined in the description for the cORR outcome measure (OM). PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Kaplan-Meier methodology was used to estimate the median DOR. The 95% confidence intervals for the median DOR were computed by the method of Brookmeyer and Crowley. Participants who did not experience death or PD were censored on the day of the last available assessment.

    Time frame: Time from the date of the first confirmed CR/PR to PD or death from any cause (Up to 32 months)

  3. PFS Rate at Month 3, 6, 9, and 12 as Determined by the Investigator According to RECIST v1.1 or RANO Criteria

    The PFS rates were calculated using the Kaplan-Meier (KM) method to estimate the percent survival probability of participants (i.e., PFS event-free: did not experience PD or death from any cause) in each treatment arm at landmark timepoints. The 95% confidence intervals for each PFS rate were computed by the method of Greenwood. PFS was defined as the time from the start of study treatment to the first occurrence of PD or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Participants who did not experience death or PD were censored on the day of the last available assessment. The number analyzed per landmark timepoint actually represents the number of participants who remained at risk of experiencing a PFS event at that timepoint. Percentages are rounded off to the nearest decimal point.

    Time frame: At Months 3, 6, 9 and 12

  4. Percentage of Participants With Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria

    Disease control rate was defined as the percentage of participants whose best response was confirmed CR, confirmed PR, or a response of CR, PR, stable disease (SD), or non-CR/non-PD for a minimum of 98 days for 28-day cycle arms or 70 days for 21-day cycle arms after the first treatment date. CR \& PR were defined per RECIST/RANO as outlined in the description for the cORR OM. SD per RECIST: Neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. SD per RANO: Participant does not qualify for CR, PR, or minor response or PD; Stable non-enhancing (T2/FLAIR) lesions or abnormalities on same or lower dose of corticosteroids compared to baseline; No new lesions or new T2 or FLAIR abnormalities apart from those consistent with radiation effect, \& no new or increased enhancement; Participants on a should be corticosteroid dose that is not greater than dose at baseline scan \& is stable or improved clinically; Clinical status, stable/improved.

    Time frame: Up to 32 months

  5. Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)

    An AE is an untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with the product. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to it. AEs were graded for severity according to NCI CTCAE v5.0. Grade 1= Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated; Grade 2=Moderate; minimal, local or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3 = Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living; Grade 4= Life-threatening consequences/urgent intervention indicated; Grade 5= Death related to adverse event.

    Time frame: From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)

07

Results

Posted Jan 8, 2025

Participant flow

A total of 252 participants with advanced unresectable or metastatic solid tumors with positive biomarker result took part in the study across 38 investigative sites in the United States.

Participant flow — Overall Study
MilestoneArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
Started265262525138231928253233
Completed23545405345161
Not completed24221212098181624202172
Withdrew: Adverse event00000000000010
Withdrew: Death1711414136712152082101
Withdrew: Lost to follow-up10102011112000
Withdrew: Reason not specified20110000001000
Withdrew: Physician decision00021000000030
Withdrew: Progressive disease00001000011020
Withdrew: Withdrawal by subject41543305028011

Outcome measures

PrimaryConfirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Primary Central Nervous System (CNS) Tumors

Confirmed objective response rate (cORR)=percentage of participants with best response as complete response (CR) or partial response (PR) for measurable disease \& CR for non-measurable disease. Confirmation=CR/PR on 2 consecutive visits ≥4 weeks apart for 3-week cycles \& ≥6 weeks apart for 4-week cycles. Per RECIST, CR=disappearance of all target lesions. PR= ≥30% decrease in sum of diameters of target lesions, in absence of CR. Per RANO, CR=complete disappearance of all measurable \& non-measurable disease for ≥4 weeks; no new lesions/abnormality on T2/FLAIR imaging; stable/improved non-enhancing lesions; participants must be off corticosteroids or on physiological doses; clinical status stable/improved. PR= ≥50% decrease in the sum of products of perpendicular diameters of measurable enhancing lesions on T2/FLAIR imaging for ≥4 weeks; no progression of non-measurable T1 disease; stable/improved non-enhancing lesions; corticosteroid dose ≤ baseline; clinical status stable/improved.

Time frame:
Up to 32 months
Reported as:
Number · percentage of participants
Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Primary Central Nervous System (CNS) Tumors
percentage of participantsArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Primary Central Nervous System (CNS) Tumors11.5 (2.4 to 30.2)20.0 (0.5 to 71.6)11.5 (2.4 to 30.2)28.0 (12.1 to 49.4)12.0 (2.5 to 31.2)0.0 (0.0 to 24.7)0.0 (0.0 to 36.9)13.0 (2.8 to 33.6)0.0 (0.0 to 17.6)0.0 (0.0 to 12.3)0.0 (0.0 to 13.7)66.7 (9.4 to 99.2)21.7 (7.5 to 43.7)33.3 (0.8 to 90.6)
SecondaryProgression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria

PFS=time from start of treatment to the first occurrence of disease progression (PD) or death from any cause, whichever occurs first, per RECIST v1.1, or RANO. Per RECIST, PD=≥20% increase in sum of diameters of lesions, using the smallest sum during the study as reference, including baseline (BL). Per RANO, PD= ≥25% increase in sum of products of perpendicular diameters of enhancing lesions compared to smallest tumor measurement at BL/best response, on stable/increasing corticosteroids (CS) dose; Significant/ ≥25% increase of T2/FLAIR non-enhancing lesion on stable/increasing CS dose compared to BL/best response after therapy start; Presence of new lesions/increase of enhancement; Clear progression of non-measurable disease; Definite clinical deterioration only due to tumor/decrease in CS dose; Failure to return for evaluation due to death/deterioration. Kaplan-Meier methodology was used to estimate PFS; patients without an event were censored on the last available assessment day.

Time frame:
Time from start of treatment to the first occurrence of disease progression or death from any cause (Up to 32 months)
Reported as:
Median · months
Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
monthsArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria4.24 (1.84 to 8.08)4.98 (1.54 to NA)3.48 (1.87 to 6.47)3.94 (2.17 to 8.38)4.73 (2.07 to 10.22)2.46 (1.77 to 5.16)3.02 (1.54 to 5.52)2.69 (1.94 to 6.18)1.87 (1.71 to 2.20)2.10 (1.64 to 3.48)3.61 (2.33 to 6.34)5.98 (1.28 to NA)4.76 (1.87 to 16.43)7.10 (1.84 to NA)
SecondaryDuration of Response (DOR) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria

DOR was defined as the time from the date of the first confirmed complete response (CR) or partial response (PR) to disease progression (PD) or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. CR \& PR were defined per RECIST or RANO as outlined in the description for the cORR outcome measure (OM). PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Kaplan-Meier methodology was used to estimate the median DOR. The 95% confidence intervals for the median DOR were computed by the method of Brookmeyer and Crowley. Participants who did not experience death or PD were censored on the day of the last available assessment.

Time frame:
Time from the date of the first confirmed CR/PR to PD or death from any cause (Up to 32 months)
Reported as:
Median · months
Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
monthsArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1 or RANO Criteria5.6 (5.3 to NA)6.5 (NA to NA)5.5 (3.7 to NA)NA (7.4 to NA)20.0 (NA to NA)——7.6 (3.7 to NA)———5.5 (4.0 to NA)NA (3.6 to NA)NA (NA to NA)
SecondaryPFS Rate at Month 3, 6, 9, and 12 as Determined by the Investigator According to RECIST v1.1 or RANO Criteria

The PFS rates were calculated using the Kaplan-Meier (KM) method to estimate the percent survival probability of participants (i.e., PFS event-free: did not experience PD or death from any cause) in each treatment arm at landmark timepoints. The 95% confidence intervals for each PFS rate were computed by the method of Greenwood. PFS was defined as the time from the start of study treatment to the first occurrence of PD or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1 or RANO. PD was defined per RECIST or RANO as outlined in the description for the PFS OM. Participants who did not experience death or PD were censored on the day of the last available assessment. The number analyzed per landmark timepoint actually represents the number of participants who remained at risk of experiencing a PFS event at that timepoint. Percentages are rounded off to the nearest decimal point.

Time frame:
At Months 3, 6, 9 and 12
Reported as:
Number · percent probability
PFS Rate at Month 3, 6, 9, and 12 as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
percent probabilityArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
3 months57.69 (38.7 to 76.68)50.00 (1.00 to 99.00)52.00 (32.42 to 71.58)52.17 (31.76 to 72.59)64.00 (45.18 to 82.82)41.03 (12.19 to 69.86)50.00 (15.35 to 84.65)48.13 (26.77 to 69.49)26.32 (6.52 to 46.12)35.56 (17.13 to 53.98)65.22 (45.75 to 84.68)66.67 (13.32 to 100.00)59.09 (38.55 to 79.64)66.67 (13.32 to 100.00)
6 months37.09 (18.15 to 56.03)50.00 (1.00 to 99.00)36.00 (17.18 to 54.82)33.20 (13.48 to 52.92)44.00 (24.54 to 63.46)20.51 (0.0 to 45.25)12.50 (0.00 to 35.42)33.69 (13.43 to 53.95)10.53 (0.00 to 24.33)11.85 (0.00 to 24.41)33.82 (14.13 to 53.51)33.33 (0.00 to 86.68)40.91 (20.36 to 61.45)66.67 (13.32 to 100.00)
9 months20.60 (4.61 to 36.59)25.00 (0.00 to 67.43)9.00 (0.00 to 20.78)28.46 (9.49 to 47.42)32.00 (13.71 to 50.29)10.26 (0.00 to 29.10)—19.25 (2.32 to 36.18)10.53 (0.00 to 24.33)3.95 (0.00 to 11.53)24.15 (6.10 to 42.21)—36.36 (16.26 to 56.46)—
12 months16.48 (1.79 to 31.17)—4.50 (0.00 to 13.08)18.97 (2.39 to 35.56)23.33 (6.46 to 40.21)——9.63 (0.00 to 22.30)——14.49 (0.00 to 29.49)—36.36 (16.26 to 56.46)—
SecondaryPercentage of Participants With Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria

Disease control rate was defined as the percentage of participants whose best response was confirmed CR, confirmed PR, or a response of CR, PR, stable disease (SD), or non-CR/non-PD for a minimum of 98 days for 28-day cycle arms or 70 days for 21-day cycle arms after the first treatment date. CR \& PR were defined per RECIST/RANO as outlined in the description for the cORR OM. SD per RECIST: Neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. SD per RANO: Participant does not qualify for CR, PR, or minor response or PD; Stable non-enhancing (T2/FLAIR) lesions or abnormalities on same or lower dose of corticosteroids compared to baseline; No new lesions or new T2 or FLAIR abnormalities apart from those consistent with radiation effect, \& no new or increased enhancement; Participants on a should be corticosteroid dose that is not greater than dose at baseline scan \& is stable or improved clinically; Clinical status, stable/improved.

Time frame:
Up to 32 months
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
percentage of participantsArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
Percentage of Participants With Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria57.7 (36.9 to 76.6)40.0 (5.3 to 85.3)34.6 (17.2 to 55.7)32.0 (14.9 to 53.5)52.0 (31.3 to 72.2)23.1 (5.0 to 53.8)37.5 (8.5 to 75.5)26.1 (10.2 to 48.4)15.8 (3.4 to 39.6)10.7 (2.3 to 28.2)32.0 (14.9 to 53.5)66.7 (9.4 to 99.2)47.8 (26.8 to 69.4)66.7 (9.4 to 99.2)
SecondaryNumber of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)

An AE is an untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with the product. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to it. AEs were graded for severity according to NCI CTCAE v5.0. Grade 1= Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated; Grade 2=Moderate; minimal, local or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3 = Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living; Grade 4= Life-threatening consequences/urgent intervention indicated; Grade 5= Death related to adverse event.

Time frame:
From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event (AE) and Severity of AEs Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
ParticipantsArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
Any Adverse Event (AE), Any Grade255252524118231927253213
Highest Severity: Grade 1 AEs30103310012010
Highest Severity: Grade 2 AEs14214910631177110110
Highest Severity: Grade 3 AEs6291111247111610382
Highest Severity: Grade 4 AEs01110004012000
Highest Severity: Grade 5 AEs20040001120011

Adverse events

Collected over From initiation of study drug until 28 days after the final dose of study drugs other than atezolizumab and until 90 days after the final dose of atezolizumab (Up to 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm B: Inavolisib (GDC-0077)19/26 (73.1%)5/26 (19.2%)25/26 (96.2%)
Arm C: Alectinib1/5 (20%)2/5 (40%)5/5 (100%)
Arm D: Ipatasertib16/26 (61.5%)6/26 (23.1%)25/26 (96.2%)
Arm E: Atezolizumab + Chemotherapy16/25 (64%)11/25 (44%)25/25 (100%)
Arm F: Trastuzumab Emtansine + Atezolizumab16/25 (64%)9/25 (36%)23/25 (92%)
Arm G: PH FDC SC6/13 (46.2%)2/13 (15.4%)11/13 (84.6%)
Arm H: PH FDC SC + Chemotherapy8/8 (100%)2/8 (25%)8/8 (100%)
Arm I: Trastuzumab Emtansine + Tucatinib14/23 (60.9%)6/23 (26.1%)23/23 (100%)
Arm J: Trastuzumab Emtansine + Atezolizumab16/19 (84.2%)7/19 (36.8%)19/19 (100%)
Arm K: Ipatasertib + Atezolizumab22/28 (78.6%)10/28 (35.7%)26/28 (92.9%)
Arm L: Ipatasertib + Atezolizumab10/25 (40%)8/25 (32%)25/25 (100%)
Arm M: Ipatasertib + Paclitaxel2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Arm N: Atezolizumab + Tiragolumab10/23 (43.5%)6/23 (26.1%)21/23 (91.3%)
Arm O: Pralsetinib1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
AnaemiaBlood and lymphatic system disorders0/260/50/260/250/250/130/82/230/190/280/250/30/231/3
DiarrhoeaGastrointestinal disorders0/260/51/260/251/250/131/80/230/192/281/250/30/231/3
Gastrointestinal fistulaGastrointestinal disorders0/260/50/260/250/250/130/80/230/190/280/251/30/230/3
Rectal haemorrhageGastrointestinal disorders0/260/50/260/250/250/130/80/230/190/280/251/30/230/3
Abdominal infectionInfections and infestations0/260/50/260/250/250/130/80/230/190/280/251/30/230/3
Clostridium difficile infectionInfections and infestations0/260/50/260/250/250/130/80/230/190/281/250/30/231/3
Colonic abscessInfections and infestations0/260/50/260/250/250/130/80/230/190/280/250/30/231/3
SepsisInfections and infestations0/260/50/261/250/250/130/80/231/190/280/251/31/230/3
Brain oedemaNervous system disorders0/260/50/260/250/250/130/80/230/190/280/250/30/231/3
SeizureNervous system disorders0/260/50/260/250/250/130/80/230/190/280/250/31/231/3
Most frequent other events
Showing 10 of 180
Most frequent other events
EventArm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: Pralsetinib
AnaemiaBlood and lymphatic system disorders1/261/52/265/255/252/130/85/231/193/281/253/36/232/3
ConstipationGastrointestinal disorders4/261/54/264/256/251/132/84/231/193/281/253/37/231/3
DiarrhoeaGastrointestinal disorders6/260/519/2616/253/255/133/88/233/1918/2818/253/34/232/3
NauseaGastrointestinal disorders7/262/513/268/256/252/131/811/236/1913/2811/253/310/231/3
FatigueGeneral disorders9/261/55/2613/2513/254/131/812/238/199/2812/253/36/231/3
StomatitisGastrointestinal disorders5/260/51/263/254/251/130/83/234/194/281/252/31/230/3
PyrexiaGeneral disorders1/260/50/262/253/251/130/82/234/192/281/251/31/232/3
Alanine aminotransferase increasedInvestigations0/260/52/261/255/250/130/86/230/191/283/252/33/231/3
Aspartate aminotransferase increasedInvestigations1/260/53/261/257/250/130/811/233/191/282/252/33/231/3
DehydrationMetabolism and nutrition disorders1/260/55/268/254/251/130/83/235/196/289/252/36/230/3

Baseline characteristics

Safety evaluable population included all participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)Arm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: PralsetinibTotal
Mean64.5 ± 11.562.6 ± 6.766.7 ± 10.066.0 ± 12.066.1 ± 12.963.8 ± 10.761.1 ± 12.864.2 ± 12.061.8 ± 10.760.3 ± 10.459.8 ± 11.457.7 ± 19.463.7 ± 11.071.3 ± 16.263.6 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Arm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: PralsetinibTotal
Female184181187515919152141146
Male818141763810910192106
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: PralsetinibTotal
Hispanic or Latino0021010211003011
Not Hispanic or Latino265242424126201726253203235
Unknown or Not Reported000010211100006
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm B: Inavolisib (GDC-0077)Arm C: AlectinibArm D: IpatasertibArm E: Atezolizumab + ChemotherapyArm F: Trastuzumab Emtansine + AtezolizumabArm G: PH FDC SCArm H: PH FDC SC + ChemotherapyArm I: Trastuzumab Emtansine + TucatinibArm J: Trastuzumab Emtansine + AtezolizumabArm K: Ipatasertib + AtezolizumabArm L: Ipatasertib + AtezolizumabArm M: Ipatasertib + PaclitaxelArm N: Atezolizumab + TiragolumabArm O: PralsetinibTotal
American Indian or Alaska Native000000000000000
Asian000010021020006
Native Hawaiian or Other Pacific Islander000000000000000
Black or African American2040412132004023
White245212420124201224233193214
More than one race000000000000000
Unknown or Not Reported001100203200009
08

Study locations

38 sites
  • Alaska Oncology and Hematology
    Anchorage, Alaska 99508, United States
  • Arizona Clinical Research Ctr
    Oro Valley, Arizona 85755-6216, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • California Cancer Associates for Research and Excellence - Encinitas
    Encinitas, California 92024-1328, United States
  • Los Angeles Hematology Oncology Medical Group
    Los Angeles, California 90017, United States
  • Pacific Cancer Care - Monterey
    Monterey, California 93940, United States
  • Kaiser Permanente - San Francisco Medical Center
    San Francisco, California 94118, United States
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Kaiser Permanente Medical Ctr
    Vallejo, California 94589, United States
  • Ventura County Hematology Oncology Specialists
    Ventura, California 93003, United States
  • Eastern CT Hematology and Oncology Associates
    Norwich, Connecticut 06360-2740, United States
  • SCRI Florida Cancer Specialists South
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists - NORTH - SCRI - PPDS
    Saint Petersburg, Florida 33705-1400, United States
  • Florida Cancer Specialists - PAN - SCRI - PPDS
    Tallahassee, Florida 32308, United States
  • Florida Cancer Specialists - EAST - SCRI - PPDS
    West Palm Beach, Florida 33401-3406, United States
  • St Luke?s Cancer Institute
    Boise, Idaho 83712, United States
  • Hematology and Oncology Clinic
    Baton Rouge, Louisiana 70809, United States
  • Saint Agnes Hospital - Baltimore - Hunt - PPDS
    Baltimore, Maryland 21229-5201, United States
  • Ascension St. John Hospital
    Detroit, Michigan 48236, United States
  • Frontier Cancer Center and Blood Institute
    Billings, Montana 59102, United States
  • Southeast Nebraska Cancer Center
    Lincoln, Nebraska 68510-2496, United States
  • New Jersey Hematology Oncology Associates LLC
    Brick, New Jersey 08724-3009, United States
  • Astera Cancer Care East Brunswick
    East Brunswick, New Jersey 08816, United States
  • Eastchester Center for Cancer Care
    Bronx, New York 10469, United States
  • New York Cancer & Blood Specialists
    Bronx, New York 10469, United States
  • Central Park Hematology and Oncology
    New York, New York 10028-0506, United States
  • Messino Cancer Centers
    Asheville, North Carolina 28806, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Tri County Hematologyoncology
    Canton, Ohio 44718, United States
  • SCRI Mark H. Zangmeister Center
    Columbus, Ohio 43219, United States
  • Kaiser Permanente Center For Health Research
    Portland, Oregon 97227, United States
  • Sarah Cannon Research Institute / Tennessee Oncology
    Chattanooga, Tennessee 37404, United States
  • The West Clinic, PC dba West Cancer Center
    Memphis, Tennessee 38138, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • The Center for Cancer and Blood Disorders - PPDS
    Fort Worth, Texas 76104-4611, United States
  • Mays Cancer Center at UT Health San Antonio MD Anderson Cancer
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University - Massey Cancer Center
    Richmond, Virginia 23219, United States
  • Northwest Medical Specialties B
    Federal Way, Washington 98003, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Dec 2023, 34 months.

Results were first posted in Jan 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2020
First posted
Nov 17, 2020
StartActual
Jan 13, 2021
Primary completionActual
Dec 4, 2023
CompletionActual
Feb 27, 2024
Results first posted
Jan 8, 2025
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04632992
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2020
Start date
Jan 13, 2021
Primary completion
Dec 4, 2023
Completion
Feb 27, 2024
Results posted
Jan 8, 2025
Last update
Jan 8, 2025

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Entrectinib · Inavolisib · Alectinib · Ipatasertib · Atezolizumab · Ado-Trastuzumab Emtansine · Pertuzumab/Trastuzumab/Hyaluronidase-zzxf · Tucatinib · Paclitaxel · Tiragolumab · Pralsetinib · Trastuzumab · Pertuzumab

Start the discussion